- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Artificial Intelligence and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Andrew T. Bayman (Andy)
News 35 results
Recognition
September 21, 2023
LMG Life Sciences Recognizes King & Spalding With Multiple Rankings in its 2023 Guide
Recognition
September 8, 2023
LMG Life Sciences Honors King & Spalding as its Government Investigations Firm of the Year and Non-IP Impact Case of Year – United States
Recognition
June 8, 2023
King & Spalding Earns Top-Tier Rankings in Legal 500 United States 2023 Guide
Recognition
June 1, 2023
Chambers USA 2023 Recognizes 186 K&S Lawyers and 84 K&S Practice Groups as Leaders in Their Fields
Events 3 results
Webinar
November 9, 2021
King & Spalding Pharmaceutical University 2021
Speaking Engagement
December 7, 2020
Andy Bayman, Kristen Fournier, Adam Spicer to Speak on ACI’s Annual Conference on Drug & Medical Device Litigation
Conference
November 15, 2016
9th Annual King & Spalding Pharmaceutical University
Insights 3 results
Article
March 11, 2021
Biden Administration - What's Ahead for the Life Sciences Industry?
Article · Source: Washington Legal Foundation
March 27, 2015
First Circuit Breathes New Life Into Branded Drug Preemption Defense